

SEROPREVELANCE OF HUMAN CYTOMEGALO VIRUS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

Thesis

Submitted for partial fulfillment of Master Degree
in Internal Medicine

BY

Mohamed Abd El Salam Abd El Wahab

*M.B.,B.Ch,
Faculty of Medicine – Mansura University*

Supervised By

Prof. Dr. Sayed Mohamed Shalaby

*Professor of Internal Medicine
Ain Shams University*

Prof. Dr. Noha Abd El Razek El Nakeeb

*Professor of Internal Medicine
Ain Shams University*

Dr. Mohamed Lotfy Soliman

*Lecturer of Internal Medicine
Ain Shams University*

Faculty of Medicine
Ain Shams University
2015

List of Contents

Title	Page No.
List of Abbreviations.....	ii
List of Tables	v
List of Figures	vii
Introduction	1
Aim of the work	3
<u>Review of Literature</u>	
• Hepatocellular Carcinoma	4
• Liver Cirrhosis	44
• Human Cytomegalovirus	61
• The Oncogenicity of Human Cytomegalovirus	72
Patients and Methods	88
Results	94
Discussion	110
Summary and Conclusion	118
Recommendations	121
References	122
Arabic Summary	--

List of Abbreviations

<i>Abbreviation</i>	<i>Term</i>
ADH2	Aldehyde dehydrogenase2
AFB1	Aflatoxin B1
AIH	Autoimmune hepatitis
ALDH2	Aldehyde dehydrogenase2
ALT	Alanine amino tranferase
AR	Androgen receptor
AST	Aspartate amino transferase
ATM	Ataxia telangiectasia mutated
BMI	Body Mass Index
CLD	Chronic Liver Disease
CYP17	Cytochrome P450c17 alpha
DC	Dendritic cell
EBV	Epstein Barr virus
ELISA	Enzyme-linked immuno sorbent assay
EPHx	Epoxide hydrolases
FGF	Fibroblast Growth Factor
GGT	Glutamyl transferase
GST	Glutathione-S transferases
GSTM1	Glutathione S-transferaseM1
HBsAg	Hepatitis B surface Antigen
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HCMV	Human Cytomegalovirus
HCV	Hepatitis C virus

<i>Abbreviation</i>	<i>Term</i>
HIV	Human Immune deficiency virus
hTERT	Human telomerase reverse transcriptase
HV	Hepatic veins
IE	Immediate early
IF	Immuno fluorescence
IFN	Interferon
IL	Interleukin
iNOS	Isoform of nitric oxide synthase
LB	Liver Biopsy
MAPK	Mitogen-activated protein kinase
MHC	Major histocompatibility complex
MMPs	Matrix metalloproteinases
NAFLD	Non-alcoholic fatty liver disease
NASH	Non- alcoholic Steatohepatitis
NK	Natural killer
OC	Oral contraceptive
PDGFR	Platelet derived Growth Factor receptor
PGE2	Prostaglandin E2
PI3-K	Phosphatidyl inositol3-kinase
PT	Prothrombin Time
PV	Portal vein
PVE	Portal vein embolization
TACE	Trans arterial chemo embolization
TAMS	Tumour- associated macrophages
TGF	Transforming Growth Factor

<i>Abbreviation</i>	<i>Term</i>
TSP-1	Thrombospondin
uPAR	Urokinase receptor
VC	Vinyl chloride
VEGF	Vascular endothelial growth factor
WHO	World Health Organization

List of Tables

Table No.	Title	Page No.
Table (1):	Geographic distribution of main risk factors for HCC worldwide	10
Table (2):	Child-Pugh score classification of severity of cirrhosis (clinical and laboratory based).....	60
Table (3):	The “seven” hallmarks of cancer	73
Table (4):	Comparison between groups as regard sex , age and physical examination.....	95
Table (5):	Comparison between all groups as regard HCMV antibodies.	96
Table (6):	Comparison between all groups as regard liver function testes.	97
Table (7):	Comparison between all groups as regard hepatitis markers.....	99
Table (8):	Comparison between HCC and CLD groups as regard AFP.	100
Table (8):	Correlation between AFP and HCMV.....	100
Table (9):	Comparison between all groups as regard renal function tests.	101
Table (10):	Comparison between all groups as regard CBC.	102
Table (11):	Correlation between CMV IgM and the Other Studied Parameters in HCC and CLD group Using Pearson Correlation Coefficient Test.	103
Table (12):	Correlation Study between CMV IgG and the Other Studied Parameters in HCC and CLD group Using Pearson Correlation Coefficient Test.	104
Table (13):	Diagnostic Performance of CMV index in Discrimination control and HCC.	105

List of Tables (Cont...)

Table No.	Title	Page No.
Table (14):	Diagnostic Performance of CMV index in Discrimination control and CLD.	107
Table (15):	Diagnostic Performance of CMV index in Discrimination HCC and CLD.	109

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	BCLC staging of HCC	39
Fig. (2):	Pathway linking chronic inflammation and oncogenesis	76
Fig. (3):	Concept of Oncomodulation.....	78
Fig. (4):	Major signaling pathways activated by HCMV that contribute to oncomodulation by HCMV	80
Fig. (5):	Bar chart between groups as regard HCMV antibodies.	96
Fig. (6):	ROC- curve Performance of CMV index in Discrimination control and HCC.....	105
Fig. (7):	Inter active dot diagram of IgM in Discrimination control and HCC.	106
Fig. (8):	Inter active dot diagram of IgG index in Discrimination control and HCC.....	106
Fig. (9):	ROC- curve Performance of CMV index in Discrimination control and CLD.....	107
Fig. (10):	Inter active dot diagram of IgM in Discrimination control and HCC.	108
Fig. (11):	Inter active dot diagram of IgG in Discrimination control and HCC.	108
Fig. (12):	ROC- curve Performance of CMV index in Discrimination HCC and CLD.....	109
Fig. (13):	Inter active dot diagram of IgM in Discrimination CLD and HCC.	110
Fig. (14):	Inter active dot diagram of IgG in Discrimination CLD and HCC.	110

INTRODUCTION

The Human Cytomegalo Virus (HCMV) infection was demonstrated in 52.3% of chronic HBV, and 36% of chronic HCV patients (*Bayram A et al., 2009*).

HCV patients co-infected with HCMV infection can be regarded as high risk groups for liver disease progression where they should be monitored for the long term outcome of the disease (*Tabll et al., 2011*).

Histologic activity scores (necroinflammation and fibrosis) of HCMV-positive patients were higher than that of HCMV-negatives in both HBV and HCV groups (*Bayram A et al., 2009*).

The Human Cytomegalo Virus (HCMV) seroprevalence was significantly higher in patients with HCC (74%) and lower in patients without Hepatpcellular Carcinoma (HCC) (*Quentin Lepiller et al., 2011*).

Preliminary histological studies from liver biopsies from HCC-positive patients highlighted that HCMV DNA can be

detected in tumour area of some of the patients studied (*Quentin Lepiller et al., 2011*).

Latent CMV and/or EBV infection may deteriorate the prognosis of HCV-infected patients. All HCV patients with cirrhosis or HCC expressed a latent CMV and EBV infection. (*Gerakari et al., 2011*).

AIM OF THE WORK

To assess the prevalence of HCMV in patients with liver cirrhosis and hepatocellular carcinoma (HCC).